Coya Therapeutics
Biotechnology Research • 
Houston, Texas, United States • 11-20 Employees
Company overview
| Headquarters | 5850 San Felipe St, Suite 500, Houston, Texas 77057, US |
| Phone number | +18005878170 |
| Website | |
| NAICS | 541714 |
| Founded | 2020 |
| Employees | 11-20 |
| Socials |
Key Contacts at Coya Therapeutics
Daniel Jordan
Senior Director, Manufacturing And Technical Operations
Arun Swaminathan
Chief Executive Officer/Member Of The Board
Coya Therapeutics Email Formats
Coya Therapeutics uses 4 email formats. The most common is {first initial} (e.g., j@coyatherapeutics.com), used 50% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial} | j@coyatherapeutics.com | 50% |
{first name} | john@coyatherapeutics.com | 21.4% |
{first initial}.{last name} | j.doe@coyatherapeutics.com | 14.3% |
{first name}.{last name} | john.doe@coyatherapeutics.com | 14.3% |
About Coya Therapeutics
Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to a sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system. Coya’s product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Coya’s 300 Series product candidates, COYA 301 and COYA 302, are biologic therapies intended to enhance Treg function and expand Treg numbers. COYA 301 is a cytokine biologic for subcutaneous administration to enhance Treg function and expand Treg numbers in vivo, and COYA 302 is a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages. These two mechanisms may be additive or synergistic in suppressing inflammation. Coya’s mission is focused on the advancement of innovative therapeutic approaches to address the significant unmet medical needs of patients with serious neurodegenerative, autoimmune, and metabolic diseases. For more information about Coya, please visit www.coyatherapeutics.com.
Coya Therapeutics revenue & valuation
| Annual revenue | $423,452 |
| Revenue per employee | $31,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $1,400,000 |
| Total funding | $41,500,000 |
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
Coya Therapeutics has 8 employees across 5 departments.
Departments
Number of employees
Funding Data
Explore Coya Therapeutics's funding history, including investment rounds, total capital raised, and key backers.
Coya Therapeutics Tech Stack
Discover the technologies and tools that power Coya Therapeutics's digital infrastructure, from frameworks to analytics platforms.
Performance
Hosting
JavaScript libraries
JavaScript libraries
Maps
WordPress themes
Page builders
JavaScript libraries
JavaScript libraries
Font scripts
JavaScript libraries
Programming languages
Switzerland
Norway
Hong Kong
Spain
Frequently asked questions
4.8
40,000 users
